🧬 The Double-Edged Blade of Antithrombotic Therapy in LVADs

🫀 New insights from EUROMACS registry! The latest JACC study explores the delicate ⚖️ trade-off between bleeding 🩸 and ischemic 🧠 events in LVAD patients. While HM3 reduces thrombotic risks, bleeding remains the dominant threat. Time to rethink the "one-size-fits-all" anticoagulation 🧪. Personalized strategies like LD-DOACs & lower INR targets may be the next frontier 🚀. Editorial call to action included! 📘 #Cardiology #LVAD #PrecisionMedicine #JACC #HM3 #BleedingRisk #Anticoagulation   👉 Read more & let's discuss.